Anglo-Swedish drug major AstraZeneca says that data from a study of its pain treatment Zomig (zolmitriptan) shows that the drug provides relief from cluster headache, a condition recognized as being one of the most painful of its type. The findings, which were presented at the 13th annual congress of the International Headache Society in Stockholm, Sweden, indicate that the 10mg formulation of the nasal spray provides significant pain relief 10 minutes after administration, compared with placebo.
Zomig was examined in a double-blind, randomized crossover out-patient study, conducted at multiple sites. Participants, 55 in total, treated their headaches with 5mg or 10mg doses of the drug, or placebo, with efficacy being assessed using a five-point severity scale.
The results showed that 52% of those that received the 5mg dosage, and 60.8% of those treated with the 10mg formulation, achieved the primary efficacy goal of relief 30 minutes post administration. The higher dose of the drug was shown to be effective at around 10 minutes after administration, compared with placebo (30.6% versus 18%).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze